Xuewen Liu Selected Research

cucurbitacin B

1/2020	Cucurbitacin B inhibits gastric cancer progression by suppressing STAT3 activity.
4/2019	Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
2/2019	Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
12/2018	Cucurbitacin B Inhibits the Hippo-YAP Signaling Pathway and Exerts Anticancer Activity in Colorectal Cancer Cells.
1/2018	Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
8/2016	Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xuewen Liu Research Topics

Disease

25	Neoplasms (Cancer) 02/2022 - 10/2014
6	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2012
5	Stomach Neoplasms (Stomach Cancer) 12/2021 - 07/2017
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 02/2019
3	Triple Negative Breast Neoplasms 01/2021 - 01/2017
2	Urinary Bladder Neoplasms (Bladder Cancer) 02/2022 - 06/2021
2	Alzheimer Disease (Alzheimer's Disease) 11/2015 - 08/2013
1	Dyskinesias (Dyskinesia) 11/2021
1	Parkinson Disease (Parkinson's Disease) 11/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 11/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2020
1	Esophageal Neoplasms (Esophageal Cancer) 04/2020
1	AIDS-Related Complex (ARC) 04/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2019
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/2019
1	Colorectal Neoplasms (Colorectal Cancer) 12/2018
1	Prostatic Neoplasms (Prostate Cancer) 09/2018
1	Glioblastoma (Glioblastoma Multiforme) 01/2018
1	Neuroinflammatory Diseases 01/2018
1	Neoplastic Cell Transformation 07/2017
1	Carcinoma (Carcinomatosis) 04/2017
1	Wounds and Injuries (Trauma) 01/2017
1	Reperfusion Injury 01/2017
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2017
1	Lung Neoplasms (Lung Cancer) 12/2015
1	Adenocarcinoma of Lung 12/2015
1	Memory Disorders (Memory Loss) 11/2015
1	Pancreatic Neoplasms (Pancreatic Cancer) 10/2014
1	Arthritis (Polyarthritis) 09/2013
1	Experimental Arthritis 09/2013
1	Myocardial Infarction 06/2011
1	Heart Failure 06/2011

Drug/Important Bio-Agent (IBA)

6	cucurbitacin BIBA 01/2020 - 08/2016
6	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 04/2019 - 08/2016
5	Proteins (Proteins, Gene)FDA Link 09/2018 - 12/2012
5	Oncogene Proteins (Oncogene Protein)IBA 01/2018 - 08/2016
3	ErbB Receptors (EGF Receptor)IBA 12/2021 - 02/2019
3	Biological ProductsIBA 12/2021 - 03/2017
3	Telomerase (Telomerase Reverse Transcriptase)IBA 04/2020 - 03/2017
3	polyphyllin IIBA 01/2020 - 07/2018
3	Cisplatin (Platino)FDA LinkGeneric 02/2019 - 07/2017
3	Pharmaceutical PreparationsIBA 07/2018 - 10/2014
2	Serpentine Asbestos (Chrysotile)IBA 02/2022 - 06/2021
2	Gefitinib (Iressa)FDA Link 01/2022 - 02/2019
2	Neuroprotective AgentsIBA 11/2021 - 04/2020
2	Tyrosine Kinase InhibitorsIBA 10/2019 - 02/2019
2	arctigeninIBA 07/2017 - 01/2017
2	Mechanistic Target of Rapamycin Complex 1IBA 07/2017 - 12/2015
1	Circular RNAIBA 02/2022
1	Cadherins (E-Cadherin)IBA 02/2022
1	Small Interfering RNA (siRNA)IBA 02/2022
1	aloe emodinIBA 01/2022
1	GTP-Binding Proteins (G-Protein)IBA 12/2021
1	cariporideIBA 11/2021
1	AntigensIBA 06/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2020
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2019
1	HydrocarbonsIBA 02/2019
1	TriterpenesIBA 02/2019
1	AMP-Activated Protein KinasesIBA 01/2019
1	ethoxysanguinarineIBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 09/2018
1	VimentinIBA 09/2018
1	EnzymesIBA 09/2018
1	pterostilbeneIBA 01/2018
1	Amyloid (Amyloid Fibrils)IBA 01/2018
1	InflammasomesIBA 01/2018
1	benzyloxycarbonyltyrosyl- valyl- alanyl- aspartic acid fluoromethyl ketoneIBA 01/2018
1	Caspase 1 (ICE Protease)IBA 01/2018
1	NexusIBA 07/2017
1	TOR Serine-Threonine KinasesIBA 07/2017
1	Anaplastic Lymphoma KinaseIBA 04/2017
1	CrizotinibIBA 04/2017
1	RNA Precursors (Precursor, mRNA)IBA 03/2017
1	LignansIBA 01/2017
1	lysophosphatidic acidIBA 01/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2016
1	Mechanistic Target of Rapamycin Complex 2IBA 12/2015
1	EdaravoneIBA 11/2015
1	AntibodiesIBA 10/2014
1	Axl Receptor Tyrosine KinaseIBA 10/2014
1	Phosphotransferases (Kinase)IBA 10/2014
1	LigandsIBA 10/2014
1	wen luo yinIBA 09/2013
1	CollagenIBA 09/2013
1	GangliosidesIBA 08/2013
1	PeriostinIBA 12/2012

Therapy/Procedure

4	Therapeutics 02/2022 - 10/2014
1	Aftercare (After-Treatment) 01/2022
1	Lasers (Laser) 01/2021
1	Radiotherapy 04/2020
1	Neoadjuvant Therapy 04/2020
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 04/2020
1	Induced Heart Arrest (Cardioplegia) 01/2017
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 06/2011